Merck & Co Inc Merck (NYSE: MRK) Announces Acquisition Of Pandion Merck & Co., Inc. (NYSE: MRK) revealed that it has signed an agreement with Pandion to acquire the clinical-stage biotechnology firm. Merck will buy Pandion through its subsidiary for $60 per share in cash.
